Breaking News, Collaborations & Alliances

Novozymes, EpiVax To Develop Diabetes Treatment

Will combine immune therapy with Albufuse technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novozymes Biopharma has entered a research agreement with EpiVax, Inc. for the development of a potential treatment for autoimmune diseases. The research will involve linking EpiVax’s Tregitope (T regulatory epitopes) immune-modulating therapy for the treatment of Type 1 diabetes to Novozymes’ Albufuse half-life extension platform, with the goal of enhancing its pharmacokinetic and pharmacodynamic properties.   “Novozymes is delighted to announce a research agreement with EpiVax in the key area ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters